|
|
|
| Research progress of Oseltamivir combined with common traditional Chinese medicine in the treatment of influenza |
| LI Linlin XIE Dongmin YU Xinxiang PENG Ningning WANG Weilin WANG Decai LI Binglong |
| School of Pharmacy, Shandong First Medical University (Shandong Academy of Medical Sciences), Shandong Province, Tai’an 271016, China |
|
|
|
Abstract Influenza (“influenza” for short) is a respiratory disease caused by the invasion of influenza virus into human body, which is highly infectious and spreads rapidly. There are many kinds of traditional Chinese medicine for treating influenza, which can be divided into antiviral, antiphlogistic and antipyretic, respiratory treatment and so on according to their respective functions. In Western medicine, Oseltamivir is currently recognized as the first-line medicine for treating influenza, and its active metabolite, Oseltamivir carboxylic acid, is a neuraminidase inhibitor, which can inhibit the activity of influenza virus and prevent the virus from separating from the cell, thereby inhibiting the spread of influenza A and B viruses. However, Oseltamivir is easy to produce drug resistance and side effects when used alone. In order to treat the concurrent symptoms in influenza more effectively, Oseltamivir is often used in combination with the above several kinds of traditional Chinese medicine for treatment, which not only reduces the side effects, but also improves the efficacy. This article reviews the research progress of Oseltamivir combined with the above-mentioned traditional Chinese medicine in the treatment of influenza.
|
|
|
|
|
|
[1] Yao J，Zhang H，Ma L，et al. Effect of traditional Chinese medicine Bupleurum in the treatment of influenza A（H1N1）[J]. Pak J Pharm Sci，2018，31（4（Special））：1713-1717.
[2] Vemula SV，Zhao J，Liu J，et al. Current Approaches for Diagnosis of Influenza Virus Infections in Humans [J]. Viruses，2016，8（4）：96.
[3] 房春晓，徐翼，谭丽梅，等.国产奥司他韦颗粒治疗儿童流行性感冒A型的疗效与安全性[J].中华实用儿科临床杂志，2015，30（16）：1273-1275.
[4] 帕提古力·哈力克．磷酸奥司他韦治疗流感样症状患者的疗效和药理分析[J]．中国保健营养：上旬刊，2013，23（6）：3239-3240.
[5] Gu YY，Shi L，Zhang DD，et al. Metabonomics delineates allergic reactions induced by Shuang-huang-lian injection in rats using ultra performance liquid chromatography-mass spectrometry [J]. Chin J Nat Med，2018，16（8）：628-640.
[6] Lin W，Huang W，Ning S，et al. De novo characterization of the Baphicacanthus cusia（Nees）Bremek transcriptome and analysis of candidate genes involved in indican biosynthesis and metabolism [J]. PLoS One，2018，13（7）：e0199788.
[7] Zhang Y，Zhang X，Fan S，et al. Desmoglein1 deficiency is a potential cause of cutaneous eruptions induced by shuanghuanglian injection [J]. Molecules，2018，23（6）：1477.
[8] 姚勤，黄桦，郑巧玲，等.高效液相色谱-串联质谱法测定人胎盘灌流液中奥司他韦和羧酸奥司他韦浓度[J].中国新药与临床杂志，2015，34（2）：143-147.
[9] 杨丽微.小柴胡颗粒配合奥司他韦治疗小儿流感的临床效果[J].医学信息，2019，32（17）：161-163.
[10] 霍炳杰，常靓，刘羽，等.银翘散在不同煎煮时间下体外抑制流感病毒及对小鼠巨噬细胞Toll样受体及其下游信号转导通路的影响[J].中华中医药学刊，2016，34（7）：1581-1584.
[11] 中华人民共和国国家卫生健康委员会.新型冠状病毒感染的肺炎诊疗方案（试行第六版）[EB/OL].[2020-02-19].http：//www.nhc.gov.cn/yzygj/s7653p/202002/8334a83 26dd94d329df3 51d7da8aefc2.shtml.
[12] 中华人民共和国国家卫生健康委员会.新型冠状病毒感染的肺炎诊疗方案（试行第七版）[EB/OL].[2020-03-03].http：//www.nhc.gov.cn/yzy-gj/s7653p/202003/46c929 4a7dfe4cef80dc7f5912eb1989.shtml.
[13] 王勇，王艺霏，马骥，等.连花清瘟胶囊联合奥司他韦治疗儿童流感病毒感染疗效及对NO、IFN-γ、IL-17表达水平的影响[J].中华中医药学刊，2020，38（1）：214-216.
[14] 梁志顺，王咏超.连花清瘟胶囊联合磷酸奥司他韦治疗流行性感冒的临床疗效及其安全性[J].临床合理用药杂志，2019，12（33）：92-93.
[15] Hong BT，Cheng YE，Cheng TJ，et al. Boronate，trifluoroborate，sulfone，sulfinate and sulfonate congeners of oseltamivir carboxylic acid：Synthesis and anti-influenza activity [J]. Eur J Med Chem，2019，163：710-721.
[16] 何军，黄清松.清开灵颗粒体外抑菌作用研究[J].赣南医学院学报，2011，31（2）：192-193.
[17] 林萌，熊丽君，陈贤娥，等.国产奥司他韦联合清开灵颗粒治疗小儿甲型流感的疗效分析[J].福建医药杂志，2019， 41（1）：74-76.
[18] 詹思延.奥司他韦安全性再聚焦——药物流行病学视角[J].药物不良反应杂志，2012，14（1）：1-3.
[19] 黄运柒.磷酸奥司他韦联合板蓝根颗粒治疗甲型H1N1流感疗效观察与护理探讨[J].海峡药学，2019，31（1）：233-234. |
|
|
|
